Skip to main content
Clinical Trials/JPRN-jRCT1071220115
JPRN-jRCT1071220115
Recruiting
未知

Real-world study on the efficacy of an adjunctive use of ipragliflozin for prevention of chronic kidney disease in patients with type 1 diabetes - IPRA-CKD

Horie Ichiro0 sites360 target enrollmentMarch 14, 2023

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Horie Ichiro
Enrollment
360
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 14, 2023
End Date
TBD
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Horie Ichiro

Eligibility Criteria

Inclusion Criteria

  • Patients will be recruited to meet all of the following criteria:
  • 1\) Diagnosed type 1 diabetes by diabetologists and had more than 5 years history of type 1 diabetes
  • 2\) A)Ipragliflozin group (n\=120\): Patients who administered ipragliflozin more than 24 months before enrollment.
  • B) Control group (n\=240\): Patients who have not administered any SGLT2 inhibitors more than 60 months before enrollment.
  • 3\) Age of between 20 and 75 years.
  • 4\) Any sexes
  • 5\) Outpatients
  • 6\) Willingness to provide informed consent

Exclusion Criteria

  • Patients with any of the following will be excluded:
  • 1\)Patients administered any SGLT2 inhibitors except for ipragliflozin during 24 months after index date.
  • 2\)Patients who administered ipragliflozin inadequately.
  • 3\) Patients who had previous history of malignancy within 5 years before enrollment or 2 years before/after index date.
  • 4\) Alcohol abuse or alcohol consumption \> 20g per day
  • 5\) Patients who underwent hemodialysis within 5 years before enrollment or 2 years before/after index date.
  • 6\) Patients who had a history of pregnancy and/or breastfeeding within 5 years before enrollment or 2 years before/after index date.
  • 7\) Willingness not to provide informed consent.
  • 8\) Judged inappropriate to participate by the study investigator.

Outcomes

Primary Outcomes

Not specified

Similar Trials